Bunker Hill Mining and Silver47 Merge: A New Force in North American Silver and Critical Minerals
Bunker Hill Mining and Silver47 have merged in a $163M all-stock deal, positioning themselves as leaders in critical minerals.
Bristol Myers Squibb's ZENBEXUS Approval: A Strategic Move in Oncology
Bristol Myers Squibb's ZENBEXUS receives FDA approval, marking a significant step in oncology and investor interest.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Ultragenyx's GENGLYCOS Approval: A Game Changer for Rare Disease Therapies
Ultragenyx's recent FDA approval for GENGLYCOS signals a significant shift in rare disease treatments.
Motorola Solutions Expands into Counter-Drone Technology: Key Takeaways from the $1.5 Billion Acquisition
Motorola Solutions' $1.5 billion acquisition of D-Fend Solutions positions the company at the forefront of counter-drone…
Ultragenyx Pharma's Surge: FDA Approval for GENGLYCOS and Its Market Implications
Ultragenyx Pharma's shares jumped ~14% following FDA approval for GENGLYCOS, highlighting its potential in the gene ther…
Moderna's Landmark Phase 3 Win: What It Means for MRNA and the Biotech Sector
Moderna's recent Phase 3 trial success has sent shockwaves through the biotech sector, propelling its stock and igniting…
Aurora Cannabis Faces Hostile Takeover: What It Means for Investors
Aurora Cannabis is confronted with a hostile takeover bid from Curaleaf, raising questions about the future of the North…
Merck's Breakthrough: Analysts React to Positive Drug Trial News
Analysts are optimistic about Merck's future after a 7.4% surge in shares following positive trial results.
Curaleaf's Hostile Bid for Aurora: Implications for Cannabis Investors
Curaleaf's hostile takeover bid for Aurora Cannabis raises critical questions for investors amid ongoing negotiations.
Amylyx Pharmaceuticals' 55% Surge: A Turning Point for Avexitide and Biotech Investors
Amylyx Pharmaceuticals saw a 55% surge following positive results from its avexitide trial, signaling strong investor co…
Moderna's Historic Phase 3 Cancer Vaccine Triumph: What Investors Need to Know
Moderna's stock saw a significant surge following its Phase 3 cancer vaccine success, indicating a pivotal moment for in…